MET and non-small cell lung carcinoma: This QSP model was rigorously calibrated and validated by referencing extensive experimental datasets (including data on signal transduction, cell viability, pharmacokinetics, tumor growth inhibition and clinical-level treatment response) for over 15 different candidate drugs for MET-aberrant NSCLC.